Is it necessary for elderly people to receive the 23-valent pneumococcal vaccine?

It is generally necessary for elderly individuals to receive the 23-valent pneumococcal vaccine. The 23-valent pneumococcal vaccine consists primarily of polysaccharide antigens from 23 serotypes of Streptococcus pneumoniae, which can induce immune responses against pneumococcal bacteria in the body. Protective antibodies typically develop within 15 days after vaccination, and protection lasts for at least five years. Therefore, vaccination with the 23-valent pneumococcal vaccine is essential for elderly people, who are a high-risk group.

Pneumococcus, also known as diplococcus pneumoniae and scientifically named Streptococcus pneumoniae, is widely distributed around the world and commonly found in nature. It often colonizes the nasopharynx of healthy individuals. Pneumococcus is one of the leading causes of death worldwide and primarily causes illness in elderly people, children, and individuals with chronic diseases or impaired immune function. For pneumococcal diseases, prevention is more effective than treatment; thus, vaccinating elderly individuals—the susceptible population—with the 23-valent pneumococcal vaccine is highly necessary.

After receiving the influenza vaccine, elderly individuals should remain on-site for observation for at least 30 minutes. This is because some individuals may experience acute allergic reactions, fainting, or other adverse events. Please cooperate fully with medical staff for on-site treatment or transfer to designated hospitals for managing suspected adverse events following immunization. Do not lower your guard on daily protective measures after vaccination. Continue to maintain good lifestyle habits such as regular exercise and balanced diet; practice good hygiene by frequently washing hands, wearing masks, and avoiding touching the mouth and nose with dirty hands; ensure indoor ventilation and avoid crowded places.